Victory Capital Management Inc. Grows Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Victory Capital Management Inc. increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 11.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 292,357 shares of the specialty pharmaceutical company's stock after purchasing an additional 29,668 shares during the quarter. Victory Capital Management Inc. owned 0.47% of Jazz Pharmaceuticals worth $36,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. HighTower Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 27.0% in the fourth quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company's stock worth $1,188,000 after buying an additional 2,054 shares during the period. Avantax Advisory Services Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $264,000. Envestnet Portfolio Solutions Inc. grew its position in Jazz Pharmaceuticals by 19.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,146 shares of the specialty pharmaceutical company's stock worth $387,000 after purchasing an additional 502 shares during the last quarter. Corient Private Wealth LLC grew its stake in Jazz Pharmaceuticals by 34.5% during the 4th quarter. Corient Private Wealth LLC now owns 10,857 shares of the specialty pharmaceutical company's stock valued at $1,335,000 after purchasing an additional 2,784 shares during the last quarter. Finally, Xponance Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 17.7% in the 4th quarter. Xponance Inc. now owns 7,946 shares of the specialty pharmaceutical company's stock valued at $979,000 after acquiring an additional 1,195 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Seamus Mulligan acquired 1,621 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the acquisition, the director owned 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JAZZ. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Finally, Morgan Stanley cut their price target on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $181.64.

Jazz Pharmaceuticals Stock Up 0.1%

Jazz Pharmaceuticals stock traded up $0.15 during midday trading on Thursday, hitting $117.49. The stock had a trading volume of 111,989 shares, compared to its average volume of 973,210. The stock has a market cap of $7.11 billion, a P/E ratio of 15.68, a P/E/G ratio of 5.60 and a beta of 0.32. The business has a fifty day moving average price of $109.79 and a 200 day moving average price of $118.13. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. Jazz Pharmaceuticals's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 EPS. Research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.